Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
Status: | Completed |
---|---|
Conditions: | Diabetes, Diabetes |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/23/2017 |
Start Date: | May 12, 2016 |
End Date: | November 1, 2017 |
Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to identify and evaluate the event rate of the composite
endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for
participants with Type 2 Diabetes mellitus (T2DM) and established cardiovascular (CV) disease
among new users of sodium-glucose co-transporter 2 inhibitor (SGLT2i) as compared with new
users of non-SGLT2i anti-hyperglycemic agent (AHA).
endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for
participants with Type 2 Diabetes mellitus (T2DM) and established cardiovascular (CV) disease
among new users of sodium-glucose co-transporter 2 inhibitor (SGLT2i) as compared with new
users of non-SGLT2i anti-hyperglycemic agent (AHA).
Inclusion Criteria:
- Type 2 diabetes mellitus (T2DM), defined as: greater than or equal to (>=) 1
anti-hyperglycemic agent (AHA) medication in the study period, and; >=1 diagnosis of
T2DM in any available diagnosis field on or prior to index
- Established cardiovascular disease, defined as >=1 diagnosis in any diagnosis field
for any of the following conditions: cerebrovascular disease; coronary artery disease
(including heart failure [HF]); peripheral artery disease
- >=1-year pre-index continuous eligibility; enrollment gaps of less than or equal to
(<=) 30 days will be considered continuous enrollment
Exclusion Criteria:
- Type 1 Diabetes mellitus (T1DM) diagnosis on or prior to the index date
- Secondary diabetes mellitus (DM) on or prior to the index date
- Missing sex data
We found this trial at
1
site
Click here to add this to my saved trials
